Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998–2017
Open Access
- 30 November 2020
- journal article
- research article
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 71 (703) , e157-e165
Abstract
Background: Prostate cancer is a leading cause of cancer- related death. Interpreting the results from trials of screening with prostate-specific antigen (PSA) is complex in terms of defining optimal prostate cancer screening policy.Aim: To assess the rates of, and factors associated with, the uptake of PSA testing and opportunistic screening (that is, a PSA test in the absence of any symptoms) in England between 1998 and 2017, and to estimate the likely rates of pre-randomisation screening and contamination (that is, unscheduled screening in the ‘control’ arm) of the UK-based Cluster Randomised Trial of PSA Testing for Prostate Cancer (CAP).Design and setting: Open cohort study of men in England aged 40–75 years at cohort entry (1998–2017), undertaken using the QResearch database.Method: Eligible men were followed for up to 19 years. Rates of PSA testing and opportunistic PSA screening were calculated; Cox regression was used to estimate associations.Results: The cohort comprised 2 808 477 men, of whom 631 426 had a total of 1 720 855 PSA tests. The authors identified that 410 724 men had opportunistic PSA screening. Cumulative proportions of uptake of opportunistic screening in the cohort were 9.96% at 5 years’, 22.71% at 10 years’, and 44.13% at 19 years’ follow-up. The potential rate of contamination in the CAP control arm was estimated at 24.50%.Conclusion: A substantial number of men in England opt in to opportunistic prostate cancer screening, despite uncertainty regarding its efficacy and harms. The rate of opportunistic prostate cancer screening in the population is likely to have contaminated the CAP trial, making it difficult to interpret the results.Keywords
This publication has 35 references indexed in Scilit:
- Prostate-Cancer Mortality at 11 Years of Follow-upNew England Journal of Medicine, 2012
- Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-upJNCI: Journal of the National Cancer Institute, 2012
- Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English citiesBJU International, 2011
- Prostate cancer incidence and mortality trends in 37 European countries: An overviewEuropean Journal of Cancer, 2010
- Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialClinical Trials, 2010
- Estimating average annual per cent change in trend analysisStatistics in Medicine, 2009
- 15-Year Followup of a Population Based Prostate Cancer Screening StudyJournal of Urology, 2009
- Prostate Specific Antigen Testing in Men Older Than 75 Years in the United StatesJournal of Urology, 2006
- Rates of prostate‐specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross‐sectional studyBJU International, 2004
- Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trialThe Prostate, 2004